| Literature DB >> 33305204 |
Chelsea Hall1,2, Rohan D D'Souza2,3.
Abstract
BACKGROUND: A core outcome set for studies on cardiac disease in pregnancy is being developed. Incorporating perspectives of patients and health care providers (HCPs) is an essential step in developing this core outcome set, and eliciting these outcomes is the objective of this study.Entities:
Year: 2020 PMID: 33305204 PMCID: PMC7710929 DOI: 10.1016/j.cjco.2020.05.010
Source DB: PubMed Journal: CJC Open ISSN: 2589-790X
Figure 1Study flowchart.
Characteristics of participants
| Pregnant women with cardiac disease (n = 13) | |
|---|---|
| Age | 34 ± 4 y (range, 26-40 y) |
| Employment | Employed full time (n = 7, 53.8%) |
| Education | Postgraduate degree (n = 2, 15.4%) |
| Ethnicity | Caucasian (n = 8, 61.5%) |
| Gestational age | 29 ± 7 wk (range, 16-37 wk) |
| Cardiac disease | Complex congenital heart disease (n = 4, 3.1%) |
| Health care providers (n = 10) | |
| Role | Cardiologist (n = 5, 50%) |
| Region, Country | Toronto, Ontario, Canada (n = 5, 50%) |
Ten pregnant women with cardiac disease participated in individual interviews and 3 in shared interviews with their spouses.
Outcomes elicited from participant interviews
| Core outcome area | Pregnant women and family members (n = 13) | Health care providers (n = 10) |
|---|---|---|
| Mortality/survival | Maternal mortality (n = 1) | Maternal mortality (n = 8) Short-term survival (n = 1) Shorter life expectancy (n = 1) |
| Physiological/clinical outcomes | ||
| Cardiac | Arrhythmias (n = 4) Heart failure (n = 2) Deterioration of cardiac/general condition (n = 2) Appropriate management of medications (n = 1) Syncope (n = 1) | Heart failure—new onset or worsening (n = 9) Arrhythmias (n = 9) Deterioration of valvular function (n = 6) Pulmonary hypertension—worsening or resistant (n = 5) Myocardial ischemia (n = 5) Persisting or declining left ventricular function (n = 4) Heart transplant rejection (n = 4) Worsening of cardiomyopathy in current or subsequent pregnancy (n = 3) Aortic root dilation (n = 3) Aortic dissection (n = 2) Deterioration in New York Heart Association functional class (n = 2) Exacerbation of symptoms of coronary disease during and after pregnancy (n = 2) Deterioration of Fontan circulation (n = 1) Angina (n = 1) Aortic aneurysm (n = 1) Aortic rupture (n = 1) Risk of intervention for aortopathy (n = 1) Reversal of intracardiac shunt (n = 1) Need for cardiac intervention in pregnancy (n = 1) |
| Congenital, familial, and genetic | Congenital defects in baby (n = 6) | Congenital defects in baby (n = 4) |
| Pregnancy, puerperium, and perinatal | General health and well-being of baby (n = 13) Healthy pregnancy/general wellness (n = 5) Health and recovery after childbirth (n = 3) Fetal growth concerns (small or large for gestational age) and overall birth weight (n = 4) Gestational diabetes (n = 1) Mode of delivery: vaginal vs caesarean (n = 1) | Fetal growth concerns (n = 10) Prematurity and associated complications (n = 9) Fetal loss including miscarriage (n = 8) Mode of delivery (n = 6) Hypertensive disorders in pregnancy (n = 3) Healthy pregnancy and healthy baby (n = 1) Compromised placental circulation (n = 1) Pregnancy termination (n = 1) |
| Other clinical outcomes | Thromboembolism (n = 10) Haemorrhage (n = 6) Stroke (n = 2) Future infertility (n = 1) | |
| Adverse events/effects | Adverse effects of medication on fetal growth and development (n = 3) | Adverse events during labour and delivery (n = 3) Adverse effects of anticoagulants (n = 3) Warfarin-induced congenital defects (n = 2) Adverse events due to medication in general (n = 2) Adverse anaesthetic events (n = 1) Adverse events due to cardiac intervention (n = 1) |
| Functioning | ||
| Resource use | Intensive care unit admission—mother or baby (n = 2) | |
Proportion of reported outcomes by core outcome area in health care user interviews, health care provider interviews, and published literature
| Core outcome areas | Pregnant woman and family members (n = 17 outcomes) | Health care providers (n = 45 outcomes) | Systematic review of published studies (n = 148 outcomes) | |
|---|---|---|---|---|
| Mortality and survival | n = 1 (5.9%) | n = 3 (6.7%) | n = 6 (4%) | > 0.99 |
| Clinical outcomes and adverse events | n = 13 (76.5%) | n = 33 (73.4%) | n = 139 (94%) | 0.03 |
| Functioning/life impact | n = 3 (17.6%) | n = 3 (6.7%) | n = 0 (0%) | < 0.0001 |
| Resource use | n = 0 (0%) | n = 1 (2.2%) | n = 3 (2%) | > 0.99 |